Stock Markets November 19, 2026 01:09 AM

EU Grants Marketing Authorization to Sanofi's Next-Generation Rabies Vaccine

VaxRabeo approved for all age groups for pre- and post-exposure use after EMA recommendation

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn

The European Commission has authorized Sanofi's VaxRabeo for prevention of rabies in all age groups across the EU for both pre-exposure and post-exposure settings. The decision follows a positive recommendation from the European Medicines Agency and is supported by clinical trials showing comparable antibody responses and durable booster effectiveness. VaxRabeo uses Vero-cell technology, aims to reduce allergic reactions, and offers extended shelf life and improved heat stability.

EU Grants Marketing Authorization to Sanofi's Next-Generation Rabies Vaccine
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The European Commission has granted marketing authorization for Sanofi's VaxRabeo for use across all age groups in the EU for both pre-exposure and post-exposure prevention.
  • Clinical trials versus Sanofi's existing vaccines, Verorab and Imovax Rabies, showed comparable protective antibody levels and high effectiveness when boosters were given at 12 or 24-36 months.
  • VaxRabeo employs Vero-cell technology, is designed to reduce allergic reactions, and offers a five-year shelf life plus stability up to 27°C for 96 hours before preparation - relevant to pharmaceutical manufacturing, distribution, and cold-chain logistics.

Overview

The European Commission has approved Sanofi's rabies vaccine, VaxRabeo, for use across all age groups in the European Union, authorizing the vaccine for both pre-exposure and post-exposure prevention of rabies. This marks the first marketing authorization for VaxRabeo and comes after a favorable opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use on September 17, 2026.

Vaccine profile and clinical evidence

VaxRabeo is based on Vero-cell technology and was developed with design features intended to lower the risk of allergic reactions. Sanofi says the vaccine demonstrates a longer shelf life compared with its existing rabies products and improved heat stability.

The EU approval was grounded in clinical trials that directly compared VaxRabeo with Sanofi's current rabies vaccines, Verorab and Imovax Rabies. Those studies evaluated the vaccine in both pre-exposure and post-exposure contexts, across all age groups, and applied World Health Organization-recommended vaccination schedules. Results showed VaxRabeo produced comparable protective antibody levels to the existing products and that it delivered high effectiveness when booster doses were administered at either 12 months or in the 24-36 month window after the initial vaccination series.

Shelf life and stability

Sanofi reports that VaxRabeo carries a five-year shelf life and maintains stability at temperatures up to 27°C for 96 hours prior to preparation for use. These attributes are highlighted as improvements relative to the company's current rabies vaccines.

Public health context

According to World Health Organization estimates cited with the approval announcement, rabies remains present in 150 countries and accounts for roughly 59,000 deaths worldwide each year. Transmission is primarily via the saliva of infected animals, most commonly through dog bites. The WHO also indicates that about 29 million people receive post-exposure rabies vaccination annually. The disease is effectively untreatable once clinical symptoms appear, rendering timely vaccination critical because the illness is almost always fatal without it.

Comment from Sanofi

Thomas Triomphe, Head of Vaccines at Sanofi, said: "Death from rabies should be prevented at all costs; it is entirely preventable with vaccination provided on time. This first approval of VaxRabeo is a proud milestone for Sanofi and reflects our commitment to rabies protection, built on five decades of expertise and innovation."

Implications and next steps

The European Commission authorization enables Sanofi to market VaxRabeo across the EU for both pre-exposure and post-exposure rabies prevention in all age groups. The approval is specifically supported by comparative clinical data versus Verorab and Imovax Rabies and by the vaccine's reported stability and shelf-life characteristics.


Note: The article reflects the regulatory decision, clinical findings cited by Sanofi, and the public health statistics referenced in the approval announcement.

Risks

  • The effectiveness evidence is limited to the clinical studies described; real-world performance and long-term outcomes will depend on post-authorization monitoring - this affects public health and healthcare providers.
  • Stability and shelf-life improvements are described relative to existing Sanofi vaccines, but logistical realities such as distribution and storage practices will determine whether those attributes materially reduce supply-chain constraints - this impacts pharmaceutical logistics and supply chain operations.
  • Regulatory approval is specific to the EU; authorization status elsewhere is not addressed in the provided information, which limits immediate global availability and affects international public health planning and vaccine market dynamics.

More from Stock Markets

L'Oréal Leads Consortium Seeking Combined 15% Stake in Armani Nov 19, 2026 Sony Shares Rise as Grand Theft Auto VI Dominates PlayStation Sales Nov 19, 2026 Flughafen Wien posts modest profit rise as Vienna traffic weakens Nov 19, 2026 UK Opens Probe into Chinese Robotic Mower Imports After Husqvarna Complaint Nov 19, 2026 UniCredit and German Authorities Agree Key Terms for Commerzbank Takeover Nov 19, 2026